mounjaro tirzepatide patent expiration when does expire Off-patent semaglutide in 2026: the next revolution in anti-obesity medications when does the patent on – Tirzepatide And Semaglutide: Experts Explain

Pharmacological interventions are indicated in patients with a BMI 30 kg/m 2 or 27 kg/m 2 in the presence of 1 obesity-related comorbidities 10

The Future of Retatrutide Retatrutide is in the final phase of clinical trials and is therefore not yet available

Oral NR has the strongest human RCT base

Phase 2 body composition data from the Lancet Diabetes and Endocrinology substudy showed retatrutide achieving fat mass reductions of 15.2% at the 4mg dose, 26.1% at 8mg, and 23.2% at 12mg, while the proportion of lean mass loss relative to total weight loss remained comparable to other GLP-1 compounds

According to the American Academy of Ophthalmology, the estimated annual incidence of NAION in the U.S

PubMed Central, Liu, Feng, et al